MX376293B - Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva. - Google Patents
Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.Info
- Publication number
- MX376293B MX376293B MX2015011388A MX2015011388A MX376293B MX 376293 B MX376293 B MX 376293B MX 2015011388 A MX2015011388 A MX 2015011388A MX 2015011388 A MX2015011388 A MX 2015011388A MX 376293 B MX376293 B MX 376293B
- Authority
- MX
- Mexico
- Prior art keywords
- mva
- immune response
- high dose
- single high
- protective immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788722P | 2013-03-15 | 2013-03-15 | |
| PCT/EP2014/000693 WO2014139687A1 (en) | 2013-03-15 | 2014-03-14 | Single high dose of mva induces a protective immune response in neonates and infants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011388A MX2015011388A (es) | 2016-02-03 |
| MX376293B true MX376293B (es) | 2025-03-07 |
Family
ID=50389388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011388A MX376293B (es) | 2013-03-15 | 2014-03-14 | Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9707291B2 (https=) |
| EP (2) | EP2968524A1 (https=) |
| JP (1) | JP6480875B2 (https=) |
| KR (1) | KR102269491B1 (https=) |
| CN (1) | CN105101993A (https=) |
| AU (4) | AU2014231229A1 (https=) |
| BR (1) | BR112015021781A2 (https=) |
| CA (1) | CA2905569C (https=) |
| EA (1) | EA034825B1 (https=) |
| HK (1) | HK1216860A1 (https=) |
| IL (1) | IL241059B (https=) |
| MX (1) | MX376293B (https=) |
| MY (1) | MY175269A (https=) |
| SG (2) | SG11201507192SA (https=) |
| UA (1) | UA126785C2 (https=) |
| WO (1) | WO2014139687A1 (https=) |
| ZA (1) | ZA201507017B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102269491B1 (ko) * | 2013-03-15 | 2021-06-25 | 버베리안 노딕 에이/에스 | 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도 |
| US10653766B2 (en) | 2014-03-12 | 2020-05-19 | Bavarian Nordic A/S | Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus |
| EP4164682A1 (en) * | 2020-06-10 | 2023-04-19 | Bavarian Nordic A/S | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9117596D0 (en) * | 1991-08-15 | 1991-10-02 | John Gibson Lifting Gear Ltd | Pulling system |
| US5471902A (en) * | 1994-02-22 | 1995-12-05 | Athenry Enterprises Limited | Tuning system for pianos |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| UA76731C2 (uk) * | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| CN100540051C (zh) * | 2002-04-19 | 2009-09-16 | 巴法里安诺迪克有限公司 | 用于接种新生儿的改良的安卡拉痘苗病毒 |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| UA100836C2 (ru) * | 2005-02-23 | 2013-02-11 | Бавариан Нордик А/С | Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов |
| EP2064351A1 (en) * | 2006-09-08 | 2009-06-03 | Bavarian Nordic A/S | Phenotypic and genotypic differences of mva strains |
| EP2303322A1 (en) * | 2008-06-20 | 2011-04-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
| AU2010305030A1 (en) * | 2009-10-08 | 2012-05-10 | Bavarian Nordic A/S | Generation of a broad T-cell response in humans against HIV |
| US9463238B2 (en) * | 2011-12-09 | 2016-10-11 | Bavarian Nordic A/S | Recombinant poxvirus vector comprising tetanus toxin fragment C |
| WO2013189611A1 (en) * | 2012-06-22 | 2013-12-27 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| KR102435054B1 (ko) * | 2012-08-01 | 2022-08-22 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
| KR102269491B1 (ko) * | 2013-03-15 | 2021-06-25 | 버베리안 노딕 에이/에스 | 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도 |
-
2014
- 2014-03-14 KR KR1020157029515A patent/KR102269491B1/ko active Active
- 2014-03-14 US US14/776,881 patent/US9707291B2/en active Active
- 2014-03-14 SG SG11201507192SA patent/SG11201507192SA/en unknown
- 2014-03-14 JP JP2015561981A patent/JP6480875B2/ja active Active
- 2014-03-14 EP EP14713036.3A patent/EP2968524A1/en not_active Ceased
- 2014-03-14 EA EA201591803A patent/EA034825B1/ru not_active IP Right Cessation
- 2014-03-14 BR BR112015021781A patent/BR112015021781A2/pt not_active Application Discontinuation
- 2014-03-14 HK HK16104937.0A patent/HK1216860A1/zh unknown
- 2014-03-14 EP EP20163606.5A patent/EP3708187A1/en active Pending
- 2014-03-14 SG SG10201707340XA patent/SG10201707340XA/en unknown
- 2014-03-14 AU AU2014231229A patent/AU2014231229A1/en not_active Abandoned
- 2014-03-14 UA UAA201509740A patent/UA126785C2/uk unknown
- 2014-03-14 CN CN201480015857.9A patent/CN105101993A/zh active Pending
- 2014-03-14 CA CA2905569A patent/CA2905569C/en active Active
- 2014-03-14 WO PCT/EP2014/000693 patent/WO2014139687A1/en not_active Ceased
- 2014-03-14 MX MX2015011388A patent/MX376293B/es active IP Right Grant
- 2014-03-14 MY MYPI2015703045A patent/MY175269A/en unknown
-
2015
- 2015-09-02 IL IL241059A patent/IL241059B/en active IP Right Grant
- 2015-09-21 ZA ZA2015/07017A patent/ZA201507017B/en unknown
-
2019
- 2019-02-12 AU AU2019200977A patent/AU2019200977A1/en not_active Abandoned
-
2020
- 2020-10-29 AU AU2020260472A patent/AU2020260472A1/en not_active Abandoned
-
2022
- 2022-09-20 AU AU2022235527A patent/AU2022235527B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL241059A0 (en) | 2015-11-30 |
| MX2015011388A (es) | 2016-02-03 |
| JP6480875B2 (ja) | 2019-03-13 |
| EA034825B1 (ru) | 2020-03-25 |
| AU2019200977A1 (en) | 2019-02-28 |
| CA2905569A1 (en) | 2014-09-18 |
| JP2016514114A (ja) | 2016-05-19 |
| CA2905569C (en) | 2023-07-25 |
| IL241059B (en) | 2020-10-29 |
| SG11201507192SA (en) | 2015-10-29 |
| KR20150129027A (ko) | 2015-11-18 |
| HK1216860A1 (zh) | 2016-12-09 |
| CN105101993A (zh) | 2015-11-25 |
| US20160030551A1 (en) | 2016-02-04 |
| NZ711569A (en) | 2021-03-26 |
| SG10201707340XA (en) | 2017-10-30 |
| MY175269A (en) | 2020-06-17 |
| ZA201507017B (en) | 2018-12-19 |
| EA201591803A1 (ru) | 2016-02-29 |
| WO2014139687A1 (en) | 2014-09-18 |
| AU2022235527B2 (en) | 2023-10-26 |
| EP2968524A1 (en) | 2016-01-20 |
| UA126785C2 (uk) | 2023-02-08 |
| EP3708187A1 (en) | 2020-09-16 |
| US9707291B2 (en) | 2017-07-18 |
| AU2022235527A1 (en) | 2022-10-13 |
| AU2020260472A1 (en) | 2020-11-26 |
| KR102269491B1 (ko) | 2021-06-25 |
| AU2014231229A1 (en) | 2015-09-17 |
| BR112015021781A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017001796A2 (pt) | composições de flagelina e seus usos | |
| TN2015000185A1 (en) | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group | |
| EA201790109A1 (ru) | Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки | |
| MX342716B (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| BR112017014088A2 (pt) | aparelho dentário que fornece superfícies oclusais expostas | |
| JO3204B1 (ar) | 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين | |
| CA2917096C (en) | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors | |
| BR112015008417A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| PH12016501968A1 (en) | Novel macrocyclic compounds | |
| PH12015501076A1 (en) | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group | |
| BR112019005329A2 (pt) | composições de oligossacarídeos de leite humano purificadas | |
| PH12016501974A1 (en) | Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides | |
| MX390304B (es) | Proceso para preparar una vacuna tetravalente atenuada contra el dengue. | |
| PH12017500637A1 (en) | Inhibitors of lysine gingipain | |
| MX2013012233A (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. | |
| WO2014205199A3 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
| MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
| MX379201B (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| MX376293B (es) | Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva. | |
| MX368117B (es) | Modulador de sabor y metodo para utilizar el mismo. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| EA201592242A1 (ru) | Производные пиридона для лечения вирусных инфекций и других заболеваний | |
| EA201690378A1 (ru) | Вакцинные композиции против наркотической зависимости | |
| PH12017500466A1 (en) | Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of growth delay in infants or children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |